Review finds newer GLP-1 agents outperform older drugs for weight loss in adults without diabetes
The review confirms a widening efficacy gap between older GLP-1 drugs such as liraglutide and newer agents, though differences in trial design limit direct comparisons.
An updated systematic review of randomized controlled trials found that newer GLP-1 receptor agonists and co-agonists produce substantially greater weight loss than older drugs in the same class in adults who have overweight or obesity but not diabetes [1]. The findings were reported on August 31, 2026 [1].
The review pooled trials of GLP-1 receptor agonists and co-agonists used for weight management in adults without diabetes, updating an earlier systematic review of the same question [1]. It received an evidence rating of 1, or “Excellent,” in the report [1]. The authors concluded that the largest weight reductions came with the newest agents, reinforcing a widening gap between first-generation drugs such as liraglutide and current options [1].
Dose and drug choice both appeared to matter. Higher doses of subcutaneous and oral semaglutide were associated with greater weight loss, and tirzepatide continued to produce substantial reductions across trials, while liraglutide had more modest effects [1]. Several premarket therapies, including agents that target both GLP-1 and amylin pathways, also produced substantial weight loss [1]. Newly evaluated GLP-1 receptor agonists showed dose-dependent reductions in body mass index and waist circumference, although effects on blood pressure were more variable [1].
In head-to-head trials, tirzepatide and CagriSema each produced greater weight loss than semaglutide [1].
Gastrointestinal adverse events were common but generally mild to moderate and were associated with dose escalation, according to the review [1]. Treatment discontinuation because of adverse events was generally uncommon, although rates appeared higher with newer oral nonpeptide agents [1].
The authors cautioned that heterogeneity in trial designs, dosing regimens and study populations — including trials that enrolled mixed groups of people with and without type 2 diabetes — limits how directly the agents can be compared [1]. The report does not list percentage weight-loss figures for individual drugs, so the size of the differences between agents in absolute terms has not been reported [1].
Why it matters for patients
For adults choosing among these medications, the review indicates that the newest agents are not interchangeable with older ones in terms of expected weight loss [1]. The gap between liraglutide and newer options such as semaglutide, tirzepatide or CagriSema appears large in the pooled data [1]. Dose also appears to matter within a given drug: higher doses of subcutaneous and oral semaglutide were linked to greater weight loss [1]. At the same time, the review ties gastrointestinal side effects to dose escalation and notes that discontinuation rates appeared higher with newer oral nonpeptide agents [1]. The review does not address cost, insurance coverage or supply, and none of those practical questions is settled by its findings [1]. It is a synthesis of trials rather than a head-to-head study designed to predict how any one person will respond [1].
What happens next
The review is an update of an earlier systematic review on GLP-1 receptor agonists for weight loss in adults without diabetes [1]. No date for a further update, and no regulatory decisions tied to this review, have been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.